This group comprises agents, which inhibit fibrinolytic activity.Combinations with vitamin K, see B02B - Vitamin K and other hemostatics.
The DDDs are based on treatment of hemorrhage associated with fibrinolysis.
Combinations with aprotinin used as local hemostatics are classified in B02BC30.